Royalty Pharma expects 2023 Portfolio Receipts of ~$3.05B, exceeding upper guidance; 11% underlying growth

Royalty Pharma plc

2023-FY EPS reported $2.53 revenue$2,354,554,000

Portfolio Receipts for FY2023 expected ~$3.05B, above prior guidance of $2.95B-$3.0B; underlying growth 11% YoY.
Net cash from operations for FY2023 ~$2.98B-$2.99B.
Announced transactions since 2020 total ~$13B, including $4.0B in 2023; synthetic royalty transactions at record $775M.
Capital deployment target of $10B-$12B from 2022-2026; longer-term potential to double annual deployment to $4B-$5B.
Portfolio investments since 2020 expected to add ~$1.2B to Portfolio Receipts in 2025 based on consensus sales forecasts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.